Drug Approval | June 12, 2022
China NMPA approves Tislelizumab for metastatic nasopharyngeal cancer
Tislelizumab is now approved in nine indications in China
Tislelizumab is now approved in nine indications in China
Centre of Excellence at Kharel comprises Skill-building Centre and Primary, Secondary and Higher Secondary schools
Plans to establish six state of the art TaCa Centre for Surgery in next 2 years in these states
TAK-003 is currently undergoing regulatory review for potential licensure in both the European Union
We have grown from $10 billion to $80 billion. India is not too far from reaching the league of top-10 countries in Biotech's global ecosystem”
TP-3654 is currently being evaluated in a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with intermediate or high-risk primary or secondary myelofibrosis.
he approved product has an estimated market size of US$ 83 million for the twelve months ending April 2022, according to IQVIA.
Ivacaftor Tablets had estimated annual sales of USD 109 million in the US.
The company will provide free Diagnostics Service- X-ray Tele Radiology Services in District Hospitals / Sub-district Hospitals / Community Health Centers in the State of Tripura.
Based on a post hoc analysis, fewer required respiratory interventions
Subscribe To Our Newsletter & Stay Updated
